Company intelligence / Profile preview

Armata BioPharma

Los Angeles, California, United States

Ownership: Private
Employees: ~60
Development stage: Other

Overview

Phase 2 Tail wind study of inhaled AP-PA02 in non-cystic fibrosis bronchiectasis patients showed encouraging results. Phase 1b/2a diSArm study of intravenous AP-SA02 completed enrollment with AP-SA02 demonstrating good tolerability at high doses. Topline data from diSArm anticipated in first half of 2025.

Therapeutic areas: Infectious Diseases
Modalities: Bacteriophage therapy
Industry: Biotech

Partnerships

Merck Sharp & Dohme Corp. (research collaboration for synthetic bacteriophage candidates targeting undisclosed infectious disease agents)

Beyond the preview

Go deeper on Armata BioPharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Armata BioPharma.

Explore the full profile